2023
Mass spectrometry on cerebrospinal fluid uncovers association of novel glycolysis biomarkers with Alzheimer’s disease in a complex clinical cohort
de Geus M, Leslie S, Wang W, Lam T, Broekman M, Neefjes S, Nairn A, Carlyle B, Arnold S. Mass spectrometry on cerebrospinal fluid uncovers association of novel glycolysis biomarkers with Alzheimer’s disease in a complex clinical cohort. Alzheimer's & Dementia 2023, 19 DOI: 10.1002/alz.078466.Peer-Reviewed Original ResearchAlzheimer's diseaseMild cognitive impairmentHospital neurology serviceNon-AD diagnosesDiagnostic lumbar puncturePrognosis of ADCerebrospinal fluid biomarkersClinic cohortFurther mechanistic studiesNeurology serviceFDG-PETBrain metabolismFluid biomarkersLumbar puncturePatient cohortClinical indicationsDisease progressionATN biomarkersClinical cohortTreatment responseComplex cohortBackground DiagnosisCSF samplesTreatment efficacyLinear regression analysis
2022
Applying Data‐Independent Acquisition Mass Spectrometry on Cerebrospinal Fluid Samples from a Neurology Clinic for Biomarker Discovery in Alzheimer’s Disease
de Geus M, Leslie S, Ramirez C, Trombetta B, Wang W, Lam T, Gotti C, Roux‐Dalvai F, Droit A, Nairn A, Arnold S, Carlyle B. Applying Data‐Independent Acquisition Mass Spectrometry on Cerebrospinal Fluid Samples from a Neurology Clinic for Biomarker Discovery in Alzheimer’s Disease. Alzheimer's & Dementia 2022, 18 DOI: 10.1002/alz.064314.Peer-Reviewed Original ResearchAlzheimer's diseaseMild cognitive impairmentPatient cohortAD-specific biomarkersNon-AD diagnosesPrognosis of ADCerebrospinal fluid samplesNeurology clinicBrain metabolismFluid biomarkersAD progressionCognitive prognosisComplex cohortBackground DiagnosisTreatment efficacyDementia diagnosisLarge-scale patient cohortsPathophysiological processesSpecific biomarkersRegulation of balanceDiagnosisCognitive AssessmentDiseaseCohortBiomarkers